Jul. 3, 2003  17  US 2003/0124176 Al  [0185]  anticholinergic antagonists: hyoscyamine sul› fate;  [0186]  anticonvulsants:  clorazepate  dipotassium,  lamotrigine, and lorazepam;  [0187]  antidiabetic agents: repaglinide, and rosiglita› zone maleate;  [0188]  anti-emetics: chlorpromazine HCl, dronab› inol, granisetron HCl, meclizine HCl, metoclopra› mide, ondansetron HCl, perphenazine, prochlorpera› zine, promethazine, and scopolamine;  [0189]  antihistamines: azelastine hydrochloride, ceti› rizine and cetirizine HCl, cyproheptadine HCl, dex› brompheniramine maleate, fexofenadine and fex› ofenadine  HCl,  loratadine,  triprolidine,  tripelenamine and diphenhydramine;  [0190]  antilipemic  agents:  HMG-CoA reductase  inhibitors such as atorvastatine, fluvastatin, lovasta› tine, pravastatin and simvastatine;  [0191]  antimigraine preparations: dihydroergotamine  mesylate,  naratriptan,  sumatriptan  succinate,  timolol, and zolmitriptan;  [0192]  antinauseants: granisetron and ondansetron;  [0193]  antipanic agents:  alprazolam, clonazepam,  paroxetine hydrochloride, sertraline, and sertraline  HCl;  [0194]  antirheumatic agents: leflunomide, methotr› exate and  NSAlDs;  [0195]  anti-ulcer agents:  ameprazole, famotidine,  lansoprazole and omerprazole;  [0196]  antiviral agents: acyclovir, penciclovir, riman› tadine hydrochloride, zanamivir, as well as nucleo› side analogues such as stavudine and zalcitabine;  [0197]  appetite stimulant: dronabinol;  [0198]  appetite suppressants: sibutramine, phenyl› propanolamine and obesity management drugs such  as  methamphetamine  (e.g.,  methamphetamine  hydrochloride), phendimetrazine tartrate, phenter› mine (e.g., phentermine hydrochloride), and sibutra› mine ( e.g., sibutramine hydrochloride monohy› drate );  [0199]  antitussive agents: dextromethorphan hydro› bromide;  [0200]  benign prostatic hyperplasia agents:  dox› azosin ( e.g., doxazosin mesylate ), finasteride, tam› sulosin, terazosin ( e.g., terazosin HCl);  [0201]  cardiovascular preparations: angiotensin con› verting enzyme inhibitors such as 3-(5-amino-l› carboxy-l S-pentyl)amino-2,3,4,5-tetrahydro-2- oxo-3  S-lH-1-benzazepine-l-acetic  acid,  l-carboxymethyl-3-l-carboxy-3-phenyl-(lS)-propy› lamino-2,3,4,5-tetrahydro-lH-(3S)-1-benzazepine- 2-one, enalapril, 3-(1-ethoxycarbonyl-3-phenyl-(IS)› propy lamina )-2,3,4,5-tetrahydro-2-oxo-(3S)› benzazepine-l -acetic acid monohydrochloride and  lisinorpril; angiotensin III receptor antagonists such  as candesartan, cilexetil, losartan potassium, valsar- tan, and telmisartan; anti-arrhythmics such as amio› darone, bretylium, disopyramide, digoxin, dofetilide,  encainide, flecainide, ibutilide and ibutilide fuma› rate, lidocaine, mexiletine, moricizine, phenytoin,  procainamide, quinidine, and tocainide; antiplatelet  drugs such as anagrelide HCl, clopidogrel bisulfate,  epoprostenol sodium, tirofiban HCl; beta-blockers  such as acebutolol, atenolol, esmolol, metoprolol,  pindolol, propafenone, propranolol, and sotalol; car› diac glycosides such as digoxin and digitoxin; car› dioprotective agents such as dexrazoxane and leu› covorin;  vasodilators  such  as  nitroglycerin;  cholinergic agents such as arecoline; diuretics; pre› and afterload reducers; inotropes such as amrinone  and milrinone; calcium channel blockers such as  verapamil, nifedipine, nicardipene, felodipine, isra› dipine, nimodipine, bepridil, amlodipine and dilt› iazem;  [0202]  central nervous system agents: bromocriptine,  –trans- l,3,4,4a,5,10~-hexahydro-4-propyl-2H-1- benzopyrano-3,4-bipyridine-9-ol  monohydrochlo› ride, zolpidem tartrate;  [0203]  central nervous system stimulants: amphet› amine, dextroamphetamine, doxapram HCl, meth› amphetamine HCl, methylphenidate HCl, pemoline,  phendimetrazine tartrate, phentermine HCl, and  sibutramine HCl monohydrate;  [0204]  depigmenting  agents:  hydroquinone  and  monobenzone;  [0205]  erectile dysfunction therapies: alprostadil and  sildenafil ( e.g., sildenafil citrate);  [0206]  gastrointestinal agents: antispasmodics such  as glycopyrolate; histamine receptor antagonists  such as famotidine; and proton pump inhibitors such  as esomeprazole, lansoprazole, omeprazole, panto› prazole, and rabeprazole sodium;  [0207]  hematinic agents: cyanocobalamin (Vitamin  B$_{12}$ ),  ferric gluconate, ferric sulfate, ferrous glucon› ate, ferrous sulfate, and folic acid;  [0208]  hemostatic drugs: desmopressin and desmo› pressin acetate;  [0209]  hypocalcemics: calcitriol;  [0210]  immunosuppressive agents: tacrolimus and  sirolimus;  [0211]  leukotriene inhibitors: montelukast sodium;  [0212]  motion sickness drugs: promethazine HCl and  scopolamine;  [0213]  muscle relaxants: baclofen, cyclobenzaprine  and cyclobenzaprine HCl, dantrolene, ritodrine HCl,  tizanidine HCl, and tolterodine tartrate;  [0214]  nicotine;  [0215]  narcotic antagonists: naloxone, particularly  naloxone hydrochloride; nutritional agents, includ› ing vitamins, minerals, essential amino acids and  fatty acids, such as chromium picolinate, cyanoco› balamin (vitamin B$_{12}$ ),  ferric glyconate, ferric sul› fate, ferrous glyconate, ferrous salt, ferrous sulfate,  folic acid, vitamin C, zinc acetate, and zinc sulfate; 